Product Description: Aflatoxin B1/KLH is one of protein/peptide and small molecule drug conjugates (PDCs), consisting of Aflatoxin B1 (HY-N6615) and KLH. PCDs are promising targeted therapeutics with better cell permeability and drug selectivity than antibody-drug conjugates (ADCs). PDCs have been widely used in research on cancer, COVID-19, and metabolic diseases[1].
Formula: N/A
References: [1]Fu C, et al. Peptide-drug conjugates (PDCs): a novel trend of research and development on targeted therapy, hype or hope? Acta Pharm Sin B. 2023 Feb;13(2):498-516.
Molecular Weight: N/A
Research Area: Cancer
Solubility: 10 mM in DMSO
Target: Bacterial;Endogenous Metabolite;Parasite